Alaya.bio

Alaya.bio is at the forefront of biotechnology research, dedicated to targeting and delivering the future of gene therapies. Alaya.bio is developing a revolutionary targeting polymeric nanoparticle that enhances the transduction efficiency of quiescent cells such as T-cells, NK-cells, and stem cells.

Alaya.bio's innovative platform eliminates the need for activation factors or cytokines, significantly reducing exhaustion of transduced cells while preserving their naive and memory phenotypes. This groundbreaking approach leads to better clinical outcomes and enhanced therapeutic potential.

Located at 139 Main Street, Cambridge, US and 16, Villa Deshayes, Paris, Île-de-France 75014, FR, Alaya.bio is committed to advancing the field of gene therapy and improving patient outcomes through cutting-edge research and development. The team at Alaya.bio is actively working to expand its capabilities and will be sharing further details about their progress soon. We invite the management team at Alaya.bio to create a customized and exclusive company showcase and product listing on our platform.